Axcella Therapeutics to Participate in the SVB Leerink Global Healthcare Conference
02/10/2022 - 07:30 AM
Fireside chat to be webcast at 9:20 a.m. ET on February 17
CAMBRIDGE, Mass. --(BUSINESS WIRE)--
Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced that company management will be participating in the SVB Leerink Global Healthcare Conference .
A live webcast of the company’s fireside chat from this event will be available on the “Investors & News” section of the Axcella’s website, www.axcellatx.com , at 9:20 a.m. ET on February 17, 2022 . A replay will be accessible on the website for 90 days following the event.
Internet Posting of Information
Axcella uses its website, www.axcellahealth.com , as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Such disclosures will be included on the company’s website in the “Investors & News” section. Accordingly, investors should monitor this portion of the company’s website, in addition to its press releases, SEC filings and public conference calls and webcasts.
About Axcella Therapeutics (Nasdaq: AXLA)
Axcella is a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using endogenous metabolic modulator (EMM) compositions. The company’s product candidates are comprised of EMMs and derivatives that are engineered in distinct combinations and ratios to restore cellular homeostasis in multiple key biological pathways and improve cellular energetic efficiency. Axcella’s pipeline includes lead therapeutic candidates in Phase 2 development for the reduction in risk of overt hepatic encephalopathy (OHE) recurrence, the treatment of Long COVID, and the treatment of non-alcoholic steatohepatitis (NASH). The company’s unique model allows for the evaluation of its EMM compositions through non-IND clinical studies or IND clinical trials. For more information, please visit www.axcellatx.com .
View source version on businesswire.com : https://www.businesswire.com/news/home/20220209005826/en/
Jason Fredette
jfredette@axcellatx.com
(857) 320-2236
Source: Axcella Therapeutics
AXLA Rankings
#5313 Ranked by Stock Gains
AXLA Stock Data
Industry
Research and Development in Biotechnology
Sector
Professional, Scientific, and Technical Services
Tags
Pharmaceuticals: Major, Biotechnology, Health Technology
About AXLA
axcella has pioneered a new therapeutic class – defined amino acid compositions (daacs™). our daac therapeutics leverage the essential signaling function of amino acids to restore health across a network of dysregulated pathways, and provide safer solutions for patients with complex disease. with our axcellerator™ platform, we are transforming traditional drug discovery and development by generating patient data in less than a year from indication selection. this platform has delivered a rich pipeline including clinical programs in liver, metabolic, cns and orphan diseases.